An Acute Migraine Factorial Study

Updated 05/17/2024

Status Completed

Clinical Trial Summary

The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06245902
Study type	Interventional
Source	Allodynic Therapeutics, Inc
Contact
Status	Completed
Phase	Phase 2
Start date	February 18, 2017
Completion date	February 8, 2018

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00792636` - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period	Phase 4
	Completed	`NCT00383162` - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)	Phase 3
	Completed	`NCT01986088` - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study	Phase 3
	Completed	`NCT02605174` - Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine	Phase 3
	Completed	`NCT01978496` - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine	Phase 3
	Completed	`NCT01989936` - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan	Phase 3
	Completed	`NCT03061734` - Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine	Phase 2
	Completed	`NCT00382993` - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)	Phase 3
	Completed	`NCT01986270` - Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo	Phase 3
	Completed	`NCT03194555` - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination	Phase 2